Please assess the completion status of the following clinical trial:

Trial Title: Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of a solid tumor malignancy~* Baseline hemoglobin value of \<11 g/dL~* Scheduled to receive cyclic chemotherapy for a minimum of 12 weeks~* \< 2 prior chemotherapy regimens in a metastatic setting~* Adequate hematologic \& renal function and platelet count \>100,000/mm3~* Estimated life expectancy of \> 6 months~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 2~Exclusion Criteria:~* History of stem cell or bone marrow transplant~* Anemia due to factors other than cancer/chemotherapy~* Prior treatment with epoetin alfa or darbepoetin alfa or any investigational forms of erythropoietin within the previous 3 months~* Significant, uncontrolled disease/dysfunction of the pulmonary, cardiovascular, endocrine, neurologic, gastrointestinal, or genitourinary systems not attributable to underlying malignancy or chemotherapy~* Uncontrolled hypertension or recent history (within 6 months) of uncontrolled cardiac arrhythmias, pulmonary embolism, thrombosis~* new onset of seizures~* history of second active malignancy~* Major infection requiring hospitalization and antibiotics within 14 days of randomization~* Transfusion of white blood cells or packed red blood cells within 28 days of randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).